Remove 2026 Remove Documentation Remove Hospitals
article thumbnail

NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027

Putting Patients First Blog

1 And we appreciated CMS’ thorough responses to comments for IPAY 2026 and hope the Agency will replicate this for this comment opportunity. The NHC requests more clarity on how CMS will exclude QALY-based metrics and highlight when they have been removed from consideration in MFP justification documentation.

article thumbnail

Cloud Computing for Pharma: The Road to Digital Transformation 

Viseven

By the end of 2026, the company will be able to analyze two million genomes. Many are still designed with life sciences companies in mind, requiring patients to make frequent hospital visits without compensation for their time or effort. Isn’t scalability one of the most important goals each drug manufacturer is striving for?

article thumbnail

NHC Submits Comments to CMS on Advance Notice of Methodological Changes for CY 2026 for Medicare Advantage Capitation Rates and Part C and Part D Payment Policies

Putting Patients First Blog

Overarching Comments The NHC acknowledges CMS efforts to implement meaningful policy updates in CY 2026 to advance equity, affordability, and access to high-value care for Medicare beneficiaries. Equally critical is clear and accessible communication with beneficiaries.